Dirk Rades1, Stefan Huttenlocher2, Niklas Gebauer3, Dagmar Hornung4, Ngo Thuy Trang5, Mai Trong Khoa5, Steven E Schild6. 1. Department of Radiation Oncology, University of Lübeck, Lübeck, Germany rades.dirk@gmx.net. 2. Department of Radiation Oncology, University of Lübeck, Lübeck, Germany. 3. Department of Medical Oncology, University of Lübeck, Lübeck, Germany. 4. Department of Radiation Oncology, University Medical Center Eppendorf, Hamburg, Germany. 5. Nuclear Medicine and Oncology Center, Bach Mai Hospital, Hanoi, Vietnam. 6. Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, U.S.A.
Abstract
AIM: Renal cell carcinoma (RCC) is a relatively radioresistant tumor and may require for higher radiation doses than other tumor types. PATIENTS AND METHODS: Nineteen patients treated with 20 Gy of stereotactic radiosurgery (SRS) alone for one to three cerebral metastases were compared to nine patients treated with 16-18 Gy. RESULTS: SRS with 20 Gy led to significantly better local control than did 16-18 Gy (81% vs. 50% at 12 months; p<0.001). Results were also significant on multivariate analysis (risk ratio: 6.30; p=0.033). SRS dose did not associate with freedom from new cerebral metastases (75% vs. 62% at 12 months; p=0.42) or survival (16% vs. 56% at 12 months; p=0.46). On multivariate analyses, better survival was associated with higher Karnofsky performance score (p<0.001) and absence of extracranial metastatic disease (p=0.006). CONCLUSION: In patients treated with SRS alone, local control of cerebral metastases from RCC was better after 20 Gy than after 16-18 Gy. Copyright
AIM: Renal cell carcinoma (RCC) is a relatively radioresistant tumor and may require for higher radiation doses than other tumor types. PATIENTS AND METHODS: Nineteen patients treated with 20 Gy of stereotactic radiosurgery (SRS) alone for one to three cerebral metastases were compared to nine patients treated with 16-18 Gy. RESULTS:SRS with 20 Gy led to significantly better local control than did 16-18 Gy (81% vs. 50% at 12 months; p<0.001). Results were also significant on multivariate analysis (risk ratio: 6.30; p=0.033). SRS dose did not associate with freedom from new cerebral metastases (75% vs. 62% at 12 months; p=0.42) or survival (16% vs. 56% at 12 months; p=0.46). On multivariate analyses, better survival was associated with higher Karnofsky performance score (p<0.001) and absence of extracranial metastatic disease (p=0.006). CONCLUSION: In patients treated with SRS alone, local control of cerebral metastases from RCC was better after 20 Gy than after 16-18 Gy. Copyright
Authors: Shankar Siva; Gargi Kothari; Alexander Muacevic; Alexander V Louie; Ben J Slotman; Bin S Teh; Simon S Lo Journal: Nat Rev Urol Date: 2017-06-20 Impact factor: 14.432
Authors: Paul W Sperduto; Brian J Deegan; Jing Li; Krishan R Jethwa; Paul D Brown; Natalie Lockney; Kathryn Beal; Nitesh G Rana; Albert Attia; Chia-Lin Tseng; Arjun Sahgal; Ryan Shanley; William A Sperduto; Emil Lou; Amir Zahra; John M Buatti; James B Yu; Veronica Chiang; Jason K Molitoris; Laura Masucci; David Roberge; Diana D Shi; Helen A Shih; Adam Olson; John P Kirkpatrick; Steve Braunstein; Penny Sneed; Minesh P Mehta Journal: Int J Radiat Oncol Biol Phys Date: 2018-04-12 Impact factor: 7.038
Authors: Ethan A Ferrel; Andrew T Roehrig; Wayne T Lamoreaux; Alexander R Mackay; Robert K Fairbanks; Jason A Call; Jonathan D Carlson; Benjamin C Ling; John J Demakas; Barton S Cooke; Aaron Wagner; Christopher M Lee Journal: Case Rep Neurol Med Date: 2015-10-27
Authors: Ethan A Ferrel; Andrew T Roehrig; Erin A Kaya; Jonathan D Carlson; Benjamin C Ling; Aaron Wagner; Alexander R MacKay; Jason A Call; John J Demakas; Wayne T Lamoreaux; Robert K Fairbanks; Barton S Cooke; Ben Peressini; Christopher M Lee Journal: Int J Mol Sci Date: 2016-03-18 Impact factor: 5.923